补体在牙周炎发生发展过程中作用的研究进展

doi:10.13481/j.1671-587x.20200532

摘要/Abstract

摘要： 牙周炎导致的牙周组织破坏是牙周微生物与宿主免疫系统相互作用的结果。虽然牙周微生物是牙周炎发生发展的始动因子，但补体系统作为机体免疫系统的重要组成部分，在对抗病原微生物入侵的同时产生免疫炎症反应，在牙周炎的病理生理过程中扮演更重要的角色。因此，了解补体系统在牙周炎发生发展过程中的作用，不仅能深入理解牙周炎的发病机制，而且能为进一步以补体系统为靶点进行牙周炎的防治提供新的策略。现从补体系统的组成、补体的激活途径及补体的生理和病理作用，补体系统的多种成分（补体C3和C5a等）介导的免疫炎症反应在牙周炎发生发展中的作用及其机制，补体参与牙周炎发生发展的临床和组织学证据以及通过阻断补体的作用来治疗牙周炎的可行性，补体临床应用存在的挑战以及可能的解决方案等方面综述补体与牙周炎的关系，以便系统深入地探讨国内外相关研究的现状及存在的问题，为进一步研究提供新方向，为牙周炎防治提供合理规范的新方案和新思路。

关键词: 牙周炎, 补体系统, 补体C3, 补体C5a, 补体C3a, 补体抑制剂

中图分类号:

R781.42s

任飞龙, 罗环宇, 郑适泽, 刘苍维, 闫广兴, 胡月, 郝新青, 史册, 孙宏晨. 补体在牙周炎发生发展过程中作用的研究进展[J]. 吉林大学学报(医学版), 2020, 46(05): 1087-1091.

REN Feilong, LUO Huanyu, ZHENG Shize, et al. Research progress in effects of complements in occurrence and development of periodontitis[J]. Journal of Jilin University(Medicine Edition), 2020, 46(05): 1087-1091.

参考文献

[1] PIHLSTROM B L, MICHALOWICZ B S, JOHNSON N W. Periodontal diseases[J]. Lancet, 2005,366(9499):1809-1820.
[2] GENCO R J, VAN DYKE T E. Prevention:Reducing the risk of CVD in patients with periodontitis[J]. Nat Rev Cardiol, 2010, 7(9):479-480.
[3] KEBSCHULL M, DEMMER R T, PAPAPANOU P N. "Gum bug, leave my heart alone!"-epidemiologic and mechanistic evidence linking periodontal infections and atherosclerosis[J]. J Dent Res, 2010, 89(9):879-902.
[4] LUNDBERG K, WEGNER N, YUCEL-LINDBERG T, et al. Periodontitis in RA-the citrullinated enolase connection[J]. Nat Rev Rheumatol, 2010, 6(12):727-730.
[5] HAN Y W, WANG X. Mobile microbiome:oral bacteria in extra-oral infections and inflammation[J]. J Dent Res, 2013, 92(6):485-491.
[6] MADIANOS P N, BOBETSIS Y A, OFFENBACHER S. Adverse pregnancy outcomes (APOs) and periodontal disease:pathogenic mechanisms[J]. J Clin Periodontol, 2013, 40(Suppl 14):S170-S180.
[7] WHITMORE S E, LAMONT R J. Oral bacteria and cancer[J]. PLoS Pathog, 2014, 10(3):e1003933.
[8] DOMINY S S, LYNCH C, ERMINI F, et al. Porphyromonas gingivalis in Alzheimer's disease brains:Evidence for disease causation and treatment with small-molecule inhibitors[J]. Sci Adv, 2019, 5(1):eaau3333.
[9] GEISINGER M L, MEALEY B L, SCHOOLFIELD J, et al. The effectiveness of subgingival scaling and root planing:an evaluation of therapy with and without the use of the periodontal endoscope[J]. J Periodontol, 2007, 78(1):22-28.
[10] GIBSON F C, GENCO C A. Porphyromonas gingivalis mediated periodontal disease and atherosclerosis:disparate diseases with commonalities in pathogenesis through TLRs[J]. Curr Pharm Des, 2007, 13(36):3665-3675.
[11] ARMITAGE G C. Classifying periodontal diseases:a long-standing dilemma[J]. Periodontol 2000, 2002, 30:9-23.
[12] HAJISHENGALLIS G. Toll gates to periodontal host modulation and vaccine therapy[J]. Periodontol 2000, 2009, 51:181-207.
[13] GAFFEN S L, HAJISHENGALLIS G. A new inflammatory cytokine on the block:re-thinking periodontal disease and the Th1/Th2 paradigm in the context of Th17 cells and IL-17[J]. J Dent Res, 2008, 87(9):817-828.
[14] GRAVES D. Cytokines that promote periodontal tissue destruction[J]. J Periodontol, 2008, 79(8 Suppl):1585-1591.
[15] HAJISHENGALLIS G. The inflammophilic character of the periodontitis-associated microbiota[J]. Mol Oral Microbiol, 2014, 29(6):248-257.
[16] ROSIER B T, MARSH P D, MIRA A. Resilience of the oral microbiota in health:mechanisms that prevent dysbiosis[J]. J Dent Res, 2018, 97(4):371-380.
[17] HAJISHENGALLIS G, KAJIKAWA T, HAJISHENGALLIS E, et al. Complement-dependent mechanisms and interventions in periodontal disease[J]. Front Immunol, 2019, 10:406.
[18] CSERHALMI M, PAPP A, BRANDUS B, et al. Regulation of regulators:role of the complement factor H-related proteins[J]. Semin Immunol, 2019,45:101341.
[19] DZIK S. Complement and coagulation:cross talk through time[J]. Transfus Med Rev, 2019,33(4):199-206.
[20] HAJISHENGALLIS G. Complement and periodontitis[J]. Biochem Pharmacol, 2010, 80(12):1992-2001.
[21] ROUMENINA L T, BARTOLUCCI P, PIRENNE F. The role of complement in post-transfusion hemolysis and hyperhemolysis reaction[J]. Transfus Med Rev, 2019,33(4):225-230.
[22] DAMGAARD C, HOLMSTRUP P, VAN DYKE T E, et al. The complement system and its role in the pathogenesis of periodontitis:current concepts[J]. J Periodont Res, 2015, 50(3):283-293.
[23] HAJISHENGALLIS G, MAEKAWA T, ABE T, et al. Complement involvement in periodontitis:molecular mechanisms and rational therapeutic approaches[J]. Adv Exp Med Biol, 2015, 865:57-74.
[24] KAPFERER-SEEBACHER I, PEPIN M, WERNER R, et al. Periodontal ehlers-danlos syndrome is caused by mutations in C1R and C1S, which encode subcomponents C1r and C1s of complement[J]. Am J Hum Genet, 2016, 99(5):1005-1014.
[25] KAJIKAWA T, BRIONES R A, RESUELLO R R G, et al. Safety and efficacy of the complement inhibitor AMY-101 in a natural model of periodontitis in non-human primates[J]. Mol Ther Methods Clin Dev, 2017, 6:207-215.
[26] VIVES-SOLER A, CHIMENOS-KÜSTNER E. Effect of probiotics as a complement to non-surgical periodontal therapy in chronic periodontitis:a systematic review[J]. Med Oral Patol Oral Cir Bucal, 2020, 25(2):e161-e167.
[27] MIYAKE K. Innate immune sensing of pathogens and danger signals by cell surface Toll-like receptors[J]. Semin Immunol, 2007, 19(1):3-10.
[28] SCHAEFER L. Extracellular matrix molecules:endogenous danger signals as new drug targets in kidney diseases[J]. Curr Opin Pharmacol, 2010, 10(2):185-190.
[29] SATO T, ABE E, JIN C H, et al. The biological roles of the third component of complement in osteoclast formation[J]. Endocrinology, 1993, 133(1):397-404.
[30] TU Z D, BU H, DENNIS J E, et al. Efficient osteoclast differentiation requires local complement activation[J]. Blood, 2010, 116(22):4456-4463.
[31] GUO R F, WARD P A. Role of C5a in inflammatory responses[J]. Annu Rev Immunol, 2005, 23:821-852.
[32] OKROJ M, HEINEGÅRD D, HOLMDAHL R, et al. Rheumatoid arthritis and the complement system[J]. Ann Med, 2007, 39(7):517-530.
[33] RITTIRSCH D, FLIERL M A, NADEAU B A, et al. Functional roles for C5a receptors in sepsis[J]. Nat Med, 2008, 14(5):551-557.
[34] MYDEL P, TAKAHASHI Y, YUMOTO H, et al. Roles of the host oxidative immune response and bacterial antioxidant rubrerythrin during Porphyromonas gingivalis infection[J]. PLoS Pathog, 2006, 2(7):e76.
[35] HAJISHENGALLIS G. Immunomicrobial pathogenesis of periodontitis:keystones, pathobionts, and host response[J]. Trends Immunol, 2014, 35(1):3-11.
[36] WINGROVE J A, DISCIPIO R G, CHEN Z, et al. Activation of complement components C3 and C5 by a cysteine proteinase (gingipain-1) from Porphyromonas (Bacteroides) gingivalis[J]. J Biol Chem, 1992, 267(26):18902-18907.
[37] HAJISHENGALLIS G, WANG M, LIANG S, et al. Subversion of innate immunity by periodontopathic bacteria via exploitation of complement receptor-3[J]. Adv Exp Med Biol, 2008, 632:203-219.
[38] WANG M, KRAUSS J L, DOMON H, et al. Microbial hijacking of complement-toll-like receptor crosstalk[J]. Sci Signal, 2010, 3(109):ra11.
[39] SCHOENGRAF P, LAMBRIS J D, RECKNAGEL S, et al. Does complement play a role in bone development and regeneration?[J]. Immunobiology, 2013, 218(1):1-9.
[40] SEPPÄNEN M, LOKKI M L, NOTKOLA I L, et al. Complement and c4 null alleles in severe chronic adult periodontitis[J]. Scand J Immunol, 2007, 65(2):176-181.
[41] ROUMENINA L T, RAYES J, FRIMAT M,et al. Endothelial cells:source, barrier, and target of defensive mediators[J]. Immunol Rev, 2016, 274(1):307-329.
[42] WANG H B, RICKLIN D, LAMBRIS J D. Complement-activation fragment C4a mediates effector functions by binding as untethered agonist to protease-activated receptors 1 and 4[J]. Proc Natl Acad Sci U S A, 2017, 114(41):10948-10953.
[43] HAJISHENGALLIS G, LIANG S, PAYNE M A, et al. Low-abundance biofilm species orchestrates inflammatory periodontal disease through the commensal microbiota and complement[J]. Cell Host Microbe, 2011, 10(5):497-506.
[44] RICKLIN D, HAJISHENGALLIS G, YANG K, et al. Complement:a key system for immune surveillance and homeostasis[J]. Nat Immunol, 2010, 11(9):785-797.
[45] EHLERS M R. CR3:a general purpose adhesion-recognition receptor essential for innate immunity[J]. Microbes Infect, 2000, 2(3):289-294.
[46] HAJISHENGALLIS G, SHAKHATREH M A, WANG M, et al. Complement receptor 3 blockade promotes IL-12-mediated clearance of Porphyromonas gingivalis and negates its virulence in vivo[J]. J Immunol, 2007, 179(4):2359-2367.
[47] LIANG S, KRAUSS J L, DOMON H, et al. The C5a receptor impairs IL-12-dependent clearance of Porphyromonas gingivalis and is required for induction of periodontal bone loss[J]. J Immunol, 2011, 186(2):869-877.
[48] MAEKAWA T, ABE T, HAJISHENGALLIS E, et al. Genetic and intervention studies implicating complement C3 as a major target for the treatment of periodontitis[J]. J Immunol, 2014, 192(12):6020-6027.